JonathanMichaelGerberMD

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Director of the UMass Cancer Center Chief of Hematology & Oncology Eleanor Eustis Farrington Chair in Cancer Research

Dr. Gerber is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
55 Lake Ave N
Worcester, MA 01655
Phone+1 774-442-3903

Fax+1 774-442-6715

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
Johns Hopkins UniversityResidency, Internal Medicine, 2002 - 2005
Johns Hopkins UniversityResidency, Orthopaedic Surgery, 1999 - 2001
Johns Hopkins University School of MedicineClass of 1999

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH Start of enrollment: 2021 Feb 28
Recruiting
Phase 1
Roles: Contact, Principal Investigator

PubMed

1 citations
Effects of donor-engrafted clonal hematopoiesis in allogeneic and autologous stem cell transplantation: a systematic review and meta-analysis.
Yiyu Xie, Vera Kazakova, Lachelle D Weeks, Jonathan M Gerber, Jesse Tai
Bone Marrow Transplantation. 2024-11-01
4 citations
Natural history of clonal haematopoiesis seen in real-world haematology settings.
Shyam A Patel, William K Gerber, Rena Zheng, Shrinkhala Khanna, Lloyd Hutchinson
British Journal of Haematology. 2024-05-01
2 citations
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial.
Han-Sol Park, Anna Yin, Caelan Barranta, John S Lee, Christopher A Caputo
JCI Insight. 2024-03-14

Abstracts/Posters

Patient Reported Financial Toxicity in Myeloproliferative Neoplasms
Jonathan M. Gerber, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Relationship of minimal residual disease (MRD) in acute lymphocytic leukemia (ALL) and putative leukemia stem cells (LSCs).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

UMass Chan Researcher Explains Convalescent Plasma’s Potential as COVID-19 TreatmentFebruary 16th, 2022
Early Use of Convalescent Plasma Treatment for COVID-19 Helps Avoid HospitalizationDecember 23rd, 2021
‘We Can Deal with This Virus': In Partnership with Johns Hopkins, UMass Medical School in Worcester Needs Volunteers to Test Early Diagnosis Coronavirus TreatmentSeptember 21st, 2020
Join now to see all